Research programme: hepatitis C virus NS5A inhibitors - Presidio Pharmaceuticals

Drug Profile

Research programme: hepatitis C virus NS5A inhibitors - Presidio Pharmaceuticals

Alternative Names: HCV NS5A inhibitors - Presidio Pharmaceuticals; PPI-1301; PPI-437; PPI-833; XTL-DOS

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XTL Biopharmaceuticals
  • Developer Presidio Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA (PO)
  • 24 Feb 2012 Presidio Pharmaceuticals' hepatitis C virus NS5A inhibitors programme is available for licensing.
  • 26 May 2010 Presidio selects a second clinical candidate, PPI 1301, for evaluation in IND-enabling studies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top